Agmatine SulfatevsCreatine

Agmatine is a polyamine neuromodulator with multiple targets: (1) NMDA receptor antagonist at the polyamine binding site (GluN1/GluN2B) — reduces excitotoxicity, pain signaling, and blocks the receptor's open channel. (2) Imidazoline I1 and I2 receptor agonist — I1 in the rostral ventrolateral medulla reduces sympathetic tone; I2 modulates monoamine oxidase and provides anxiolytic/antidepressant effects. (3) Selective nNOS (neuronal nitric oxide synthase) inhibitor — reduces peroxynitrite formation and oxidative stress while preserving eNOS (endothelial) function for vascular health. (4) Alpha-2 adrenergic receptor agonist — reduces norepinephrine release from locus coeruleus, promoting calm. (5) Modulates opioid receptors — enhances mu-opioid analgesia, potentiates delta-opioid, and may reduce tolerance via nitric oxide and NMDA mechanisms.

Creatine is phosphorylated by mitochondrial creatine kinase (CK-Mt) to form phosphocreatine (PCr), which serves as a rapidly mobilizable high-energy phosphate reserve. When neuronal ATP is consumed during demanding tasks (synaptic vesicle cycling, ion pump activity, action potential propagation), cytosolic brain-type creatine kinase (CK-BB) catalyzes the transfer of the phosphoryl group from PCr to ADP, regenerating ATP within milliseconds — far faster than oxidative phosphorylation or glycolysis can respond. This PCr/CK shuttle also transports high-energy phosphates from mitochondria to distant synaptic sites. Creatine provides direct neuroprotection by stabilizing the mitochondrial permeability transition pore (mPTP), preventing cytochrome c release and downstream apoptotic cascades. It scavenges reactive oxygen species by acting as a direct antioxidant against superoxide and peroxynitrite. Creatine also increases GLUT4 expression in neurons, improving glucose uptake, and upregulates brain-derived neurotrophic factor (BDNF) expression in the hippocampus, supporting synaptic plasticity and memory consolidation.